<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1701233109
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zodric 5 mg per 100 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1189.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Zodric</strong>&reg; contains the active substance zoledronic acid. It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with corticosteroids used to treat inflammation, and Paget&rsquo;s disease of the bone in adults.</p><p>&nbsp;</p><p><strong>Osteoporosis</strong></p><p>Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in<strong> </strong>women after the menopause, but can also occur in men. At the menopause, a woman&rsquo;s ovaries stop<strong> </strong>producing the female hormone estrogen, which helps keep bones healthy. Following the menopause<strong> </strong>bone loss occurs, bones become weaker and break more easily. Osteoporosis could also occur in<strong> </strong>men and women because of the long-term use of steroids, which can affect the strength of bones.<strong> </strong>Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because<strong> </strong>osteoporosis has made their bones weaker. Decreased circulating levels of sex hormones, mainly oestrogens converted from androgens, also play a role in the more gradual bone loss observed<strong> </strong>in men. In both women and men, <strong>Zodric</strong>&reg; strengthens the bone and therefore makes it less likely to<strong> </strong>break. <strong>Zodric</strong>&reg; is also used in patients who have recently broken their hip in a minor trauma such as a<strong> </strong>fall and therefore are at risk of subsequent bone breaks.</p><p><strong>Paget&rsquo;s disease of the bone</strong></p><p>It is normal that old bone is removed and is replaced with new bone material. This process is called remodeling. In Paget&rsquo;s disease, bone remodeling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal. If the disease is not treated, bones may become deformed and painful, and may break. <strong>Zodric</strong>&reg; works by returning the bone remodeling process to normal, securing formation of normal bone, thus restoring strength to the bone</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given <strong>Zodric</strong>&reg;.</p><p><strong>You must not be given Zodric&reg;:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to zoledronic acid, other bisphosphonates or any of the other ingredients of this<strong> </strong>medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have hypocalcaemia, (this means that the levels of calcium in your blood are too low).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before you are given <strong>Zodric</strong>&reg;:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with any medicine containing zoledronic acid, which is also the active substance of <strong>Zodric</strong>&reg; (zoledronic acid is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a kidney problem, or used to have one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are unable to take daily calcium supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had some or all of the parathyroid glands in your neck surgically removed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had sections of your intestine removed.</p><p>A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported in the post-marketing setting in patients receiving <strong>Zodric</strong>&reg; (zoledronic acid) for osteoporosis. ONJ can also occur after stopping treatment.</p><p>It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to treat. In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take.</p><p>Before receiving <strong>Zodric</strong>&reg; treatment, tell your doctor, pharmacist or nurse if you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you do not receive routine dental care or have not had a dental check-up for a long time;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a smoker (as this may increase the risk of dental problems);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking medicines called corticosteroids (such as prednisolone or dexamethasone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have cancer.</p><p>Your doctor may ask you to undergo a dental examination before you start treatment with <strong>Zodric</strong>&reg; While being treated with <strong>Zodric</strong>&reg;, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups. If you wear dentures, you should make sure these fit properly. If you are under dental treatment or are due to undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with <strong>Zodric</strong> &reg;. Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring test</strong></p><p>Your doctor should do a blood test to check your kidney function (levels of creatinine) before each dose of <strong>Zodric</strong> &reg;. It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving <strong>Zodric</strong> &reg;, as directed by your healthcare provider.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p><strong>Zodric</strong>&reg; is not recommended for anyone under 18 years of age. The use of <strong>Zodric</strong> &reg; in children and adolescents has not been studied.</p><p><strong>Other medicines and Zodric&reg;</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>It is important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (&ldquo;water pills&rdquo;) that may cause dehydration.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You must not be given <strong>Zodric</strong>&reg; if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby.</p><p>Ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>If you feel dizzy while taking <strong>Zodric</strong>&reg;, do not drive or use machines until you feel better.</p><p><strong>Zodric&reg; contains sodium</strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml vial of Zodric&reg;, i.e., essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor or nurse. Check with your doctor or nurse if you are not sure.</p><p><strong>Osteoporosis</strong></p><p>The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse. The infusion will take at least 15 minutes.</p><p>In case you recently broke your hip, it is recommended that <strong>Zodric</strong>&reg; is administered two or more weeks after your hip repair surgery.</p><p>It is important to take calcium and vitamin D supplements (for example tablets) as directed by your doctor.</p><p>For osteoporosis, Zodric&reg; works for one year. Your doctor will let you know when to return for your next dose.</p><p><strong>Paget&rsquo;s disease</strong></p><p>For the treatment of Paget&rsquo;s disease, <strong>Zodric</strong>&reg; should be prescribed only by physicians with experience in the treatment of Paget&rsquo;s disease of the bone.</p><p>The usual dose is 5 mg, given to you as one initial infusion into a vein by your doctor or nurse. The infusion will take at least 15 minutes. <strong>Zodric</strong>&reg; may work for longer than one year, and your doctor will let you know if you need to be treated again.</p><p>Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given <strong>Zodric</strong>&reg;. It is important that you follow this advice carefully so that the level of calcium in your blood does not become too low in the period after the infusion. Your doctor will inform you regarding the symptoms associated with hypocalcaemia.</p><p><strong>Zodric&reg; with food and drink</strong></p><p>Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with <strong>Zodric</strong>&reg;, as directed by your doctor. This will help to prevent dehydration. You may eat normally on the day you are treated with Zodric&reg;. This is especially important in patients who take diuretics (&ldquo;water pills&rdquo;) and in elderly patients (age 65 years or over).</p><p><strong>&nbsp;</strong></p><p><strong>If you missed a dose of Zodric&reg;</strong></p><p>Contact your doctor or hospital as soon as possible to re-schedule your appointment.</p><p><strong>&nbsp;</strong></p><p><strong>Before stopping Zodric&reg; therapy</strong></p><p>If you are considering stopping <strong>Zodric</strong>&reg; treatment, please go to your next appointment and discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with <strong>Zodric</strong>&reg;.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions. The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of <strong>Zodric</strong>&reg;. The symptoms are usually mild to moderate and go away within three days. Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects. The chance of experiencing these side effects decreases with subsequent doses of <strong>Zodric</strong>&reg;.</p><p><strong>Some side effects could be serious</strong></p><p>Common (may affect up to 1 in 10 people)</p><p>Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving <strong>Zodric</strong>&reg; for the treatment of postmenopausal osteoporosis. It is currently unclear whether <strong>Zodric</strong>&reg; causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received <strong>Zodric</strong>&reg;.</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>Swelling, redness, pain and itching to the eyes or eye sensitivity to light</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>Pain in the mouth and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth; these could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with <strong>Zodric</strong>&reg; or after stopping treatment.</p><p>Kidney disorders (e.g. decreased urine output) may occur. Your doctor should do a blood test to check your kidney function before each dose of <strong>Zodric</strong>&reg;. It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving <strong>Zodric</strong>&reg;, as directed by your healthcare provider.</p><p>If you experience any of the above side effects, you should contact your doctor immediately.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Zodric&reg; may also cause other side effects</strong></p><p>Very common (may affect more than 1 in 10 people)</p><p>Fever</p><p>Common (may affect up to 1 in 10 people)</p><p>Headache, dizziness, sickness, vomiting, diarrhea, pain in the muscles, pain in the bones and/or joints, pain in the back, arms or legs, flu-like symptoms (e.g. tiredness, chills, joint and muscle pain), chills, feeling of tiredness and lack of interest, weakness, pain, feeling unwell, swelling and/or pain at the infusion site.</p><p>In patients with Paget&rsquo;s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>Flu, upper respiratory tract infections, decreased red cell count, loss of appetite, sleeplessness, sleepiness which may include reduced alertness and awareness, tingling sensation or numbness, extreme tiredness, trembling, temporary loss of consciousness, eye infection or irritation or inflammation with pain and redness, spinning sensation, increased blood pressure, flushing, cough, shortness of breath, upset stomach, abdominal pain, constipation, dry mouth, heartburn, skin rash, excessive sweating, itching, skin reddening, neck pain, stiffness in muscles, bones and/or joints, joint swelling,</p><p>muscle spasms, shoulder pain, pain in your chest muscles and rib cage, joint inflammation, muscular weakness, abnormal kidney test results, abnormal frequent urination, swelling of hands, ankles or feet, thirst, toothache, taste disturbances.</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thighbone. Low levels of phosphate in the blood.</p><p>Not known (frequency cannot be estimated from the available data)</p><p>Severe allergic reactions including dizziness and difficulty breathing, swelling mainly of the face and throat, decreased blood pressure, dehydration secondary to post-dose symptoms such as fever, vomiting and diarrhea.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor, pharmacist or nurse knows how to store <strong>Zodric</strong>&reg; properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the Bag after EXP.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C. After opening the Bag, the product should be used immediately in order to avoid microbial contamination. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2&deg;C&nbsp; 8&deg;C. Allow the refrigerated solution to reach room temperature before administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is zoledronic acid. Each Bag with 100 ml of solution contains 5 mg zoledronicacid (as monohydrate).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One ml solution contains 0.05 mg zoledronic acid (as monohydrate).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol, sodium citrate and water for injections.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zodric® is a clear and colorless solution. It comes in Polyolefin Bags 100 ml with Plug for bag, ready to-use solution for infusion.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>MS Pharma- Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July,2021
SPM-14-0021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زودريك&reg; على المادة الفعالة وهي حمض زوليدرونيك. &nbsp;ينتمي هذا الدواء إلى فئة من الادوية تدعى بيسفوسفاتيز ويستخدم في علاج هشاشة العظام في السيدات في فترة سن اليأس وفي الرجال البالغين، أو في حالات هشاشة العظام الناتجة عن العلاج بأدوية الكورتيكوستيرويد المستخدم في علاج الالتهاب، أو مرض باجت الذي يحدث في العظام لدي البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هشاشة</strong><strong> </strong><strong>العظام</strong></p><p dir="RTL">هشاشة العظام هو مرض يحدث فيه ترقق (نقص كثافة) العظام وضعفها وهو شائع عند النساء بعد وصولهن لسن اليأس (فترة انقطاع الحيض) ولكنه قد يحدث أيضا في الرجال.</p><p dir="RTL">في أثناء فترة انقطاع الحيض؛ يتوقف مبيض الأنثى عن انتاج الهرمونات الأنثوية مثل الإستروجين والذي يساعد في الحفاظ على صحة العظام. يحدث فقد في كثافة العظام بعد انقطاع الحيض كما يصبح العظم أكثر ضعفا مع سهولة أكبر في تعرضه للكسر. يمكن أن يحدث هشاشة العظام عند الرجال والنساء بسبب الاستخدام طويل الأمد لأدوية الكورتيكوستيرويد، والتي يمكن أن تؤثر على قوة العظام. العديد من المرضى المصابين بهشاشة العظام لا يعانون من ظهور أعراض، لكنهم مازالوا عرضة لخطر كسر العظام لأن مرض هشاشة العظام جعل عظامهم أضعف. نقص مستويات الهرمونات الجنسية المنتشرة في الدم خاصة الإستروجين المتحول من الأندروجين (هرمونات الذكورة)، يلعب أيضا دورا في سرعة فقدان كثافة العظام في الرجال يعمل زودريك&reg; على تقوية العظام في كل من النساء والرجال وبالتالي يجعلها أقل عرضة للكسر. يستخدم زودريك&reg; أيضًا في المرضى الذين عانوا مؤخرًا من كسر في الورك / الحوض إثر إصابة طفيفة مثل السقوط، لذلك فهم أكثر عرضة للإصابة بكسور في العظام لاحقا.</p><p dir="RTL"><strong>مرض</strong><strong> </strong><strong>باجت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>العظام</strong></p><p dir="RTL">من الطبيعي أن يتم استبدال مكونات العظم القديم بأخر جديد. تسمي هذه العملية بإعادة البناء أو التجديد. في مرض باجت؛ فإن عملية تجديد العظام سريعة جدا وذلك يتسبب في تكوين العظام الجديدة بصورة مختلة، مما يجعلها أضعف من المعتاد. إذا لم يتم علاج هذا المرض، فقد يصبح العظم مشوها ومؤلما ويمكن أن يتعرض للكسر. &nbsp;يعمل زودريك عبر إعادة عملية تجديد العظام إلى صورتها الطبيعية، وبذلك يتضمن تكوين عظام طبيعية مما ينتج عنه استعادة لقوة العظام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع كافة الارشادات التي نصحك بها الطبيب أو الممرضة أو الصيدلي بعناية قبل تناول هذا الدواء.</p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>زودريك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية مفرطة لحمض زوليدرونيك أو لأي دواء آخر من مجموعة بيسفوسفاتيز أو لأي مكونات أخرى تدخل في تركيب هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص الكالسيوم في الدم (ذلك يعني أن مستويات الكالسيوم في الدم لديك قليلة جدا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تقومين بالرضاعة الطبيعية.</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">قم بإبلاغ الطبيب قبل تناول هذا الدواء، في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالج بأي دواء يحتوي على حمض زوليدرونيك، والذي يعد أيضا مادة فعالة في دواء زودريك (يستخدم حمض زوليدرونيك في المرضى البالغين في بعض أنواع السرطان من أجل الحماية من الإصابة بمضاعفات العظام أو من أجل إنقاص مستوى الكالسيوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليا أو في السابق من مشاكل في الكلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير قادر على تناول مكملات الكالسيوم اليومية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أجريت عملية جراحية لاستئصال الغدد جار الدرقية كلها أو بعضها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لعملية جراحية لاستئصال جزء من الأمعاء.</p><p dir="RTL">تم الإبلاغ -في مرحلة ما بعد نزول الدواء إلى السوق -عن الإصابة بعرض جانبي يسمى نخر عظام الفك (تلف في عظام الفك) وذلك في المرضى الذين يتناولون دواء زودريك&reg; من أجل علاج هشاشة العظام. قد يحدث نخر عظام الفك أيضا بعد التوقف عن تناول هذا الدواء.</p><p dir="RTL">من الضروري المحاولة في منع حدوث نخر عظام الفك لأنها حالة مؤلمة وقد يصعب علاجها. هنالك بعض الاحتياطات التي يجب عليك اتخاذها من أجل تقليل مخاطر الإصابة بنخر عظام الفك.</p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة أو الصيدلي قبل تناول هذا الدواء في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أية مشاكل في الفم أو الأسنان مثل سوء صحة الأسنان أو مرض في اللثة أو كنت تخطط لإجراء خلع للأسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تتلقى رعاية روتينية للأسنان أو لم تخضع لفحص الأسنان منذ مدة طويلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مدخنا (لأن ذلك قد يزيد من خطورة تعرضك لمشاكل في الأسنان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق وأن تمت معالجتك بأدوية بيسفوسفاتيز (تستخدم في العلاج أو الوقاية من أمراض العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية تسمي الكورتيكوستيرويد (مثل دواء بردنيزولون أو ديكساميثازون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من السرطان.</p><p dir="RTL">قد يطلب منك الطبيب الخضوع لفحص الأسنان قبل البدء بتناول هذا الدواء. &nbsp;يجب أن تحافظ على النظافة الجيدة للفم والأسنان (بما في ذلك تنظيف/ تفريش الأسنان بصورة منتظمة) أثناء علاجك بهذا الدواء.</p><p dir="RTL">إذا كنت ترتدي طقم أسنان، فيجب أن تتأكد بأنه مناسب لك. &nbsp;إذا كنت تتلقى علاجا خاصا بالأسنان أو ستخضع قريبا لإجراء عملية جراحية في الأسنان) على سبيل المثال؛ خلع الأسنان (فيجب أن تخبر الطبيب عن علاج الأسنان بالإضافة إلى إخبار طبيب الأسنان بأنك تتناول هذا الدواء.</p><p dir="RTL">استشر الطبيب المُعالج وطبيب الأسنان على الفور إذا واجهت أي مشاكل في الفم أو الأسنان مثل تراخي الأسنان أو الألم أو التورم أو عدم التئام الجروح أو الإفرازات، حيث يمكن أن تكون هذه علامات لحالة تسمى نخر عظم الفك.</p><p dir="RTL"><strong>اختبارات</strong><strong> </strong><strong>المتابعة</strong></p><p dir="RTL">ينبغي أن يقوم الطبيب بإجراء فحوصات الدم من أجل فحص وظيفة الكلية) مستوى الكرياتينين (قبل تناول كل جرعة من هذا الدواء. من الضروري شرب كوبين من السوائل على الأقل) مثل الماء (في غضون الساعات التي تسبق تناول هذا الدواء، وذلك وفقا لما أوضحه لك مقدم الرعاية الصحية.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقين</strong></p><p dir="RTL">لا ينصح بتناول دواء <strong>زودريك</strong>&reg; في المرضى الأقل من 18 عاما. لم يتم دراسة استخدام دواء <strong>زودريك</strong>&reg; في الأطفال والمراهقين.</p><p dir="RTL"><strong>تناول أدوية أخرى مع زودريك&reg;</strong></p><p dir="RTL">يجب إخبار الطبيب أو الصيدلي أو الممرضة إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر.</p><p dir="RTL">يجب أن يعرف الطبيب كافة الأدوية التي تتناولها خاصة إذا كنت تتناول أية أدوية قد تشكل ضررا على الكلية) مثل: الأمينوغليكوسايد) أو الأدوية المدرة للبول) أقراص المياه (التي قد تتسبب في الإصابة بالجفاف.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب تجنب تناول هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل.</p><p dir="RTL">بجب استشارة الطبيب أو الصيدلي أو الممرضة قبل تناول هذا دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بالدوار أثناء تناولك هذا الدواء فيجب أن تتجنب القيادة أو استخدام الآلات ريثما تستعيد حالتك الطبيعية.</p><p dir="RTL"><strong>يحتوي زودريك&reg; على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ ملي مول من الصوديوم (22 ملغم) لكل ١٠٠ مل من العبوة يعني ذلك أنه يُعد خاليا من الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع كافة الارشادات التي نصحك بها الطبيب أو الممرضة بعناية. يرجى التوجه بالسؤال للطبيب أو الممرضة في حالة عدم تأكدك من أي شيء.</p><p dir="RTL"><strong>هشاشة العظام</strong></p><p dir="RTL">الجرعة الاعتيادية هي 5 ملغم تعطى عبر التنقيط الوريدي مرة في السنة بواسطة الطبيب أو الممرضة. سيستمر التنقيط الوريدي لمدة لا تقل عن 15 دقيقة.</p><p dir="RTL">في حال إن كنت تعاني مؤخرًاً من كسر 4 عظم الورك / الحوض. فيوصى بإعطاء <strong>زودريك</strong>&reg; بعد أسبوعين أو أكثر من جراحة إصلاح مفصل الورك.</p><p dir="RTL">من الضروري أن تتناول مكملات الكالسيوم وفيتامين د (الأقراص على سبيل المثال) وفقاً لما ينصحك به الطبيب.</p><p dir="RTL">في حالات هشاشة العظام. فإن فاعلية دواء <strong>زودريك</strong>&reg; تستمر لمدة عام واحد. سيخيرك الطبيب بالموعد المحدد لك الرجوع فيه من أجل تلقي الجرعة التالية.</p><p dir="RTL"><strong>مرض باجت</strong></p><p dir="RTL">لا يتم وصف هذا الدواء من أجل علاج مرض باجت إلا بواسطة الطبيب المختص والذي يمتلك خبرة في علاج مرض باجت في العظام.</p><p dir="RTL">الجرعة الاعتيادية هي 5 ملغم تعطى كجرعة واحدة أوّلية عبر التنقيط الوريدي بواسطة الطبيب أو الممرضة. سيستمر التنفيط الوريدي لمدة لا تقل عن 15 دقيقة. قد تستمر فاعلية دواء <strong>زودريك</strong>&reg; لمدة تزيد عن العام. سيخبرك الطبيب إذا كنت بحاجة إلى تلقي العلاج مرة أخرى.</p><p dir="RTL">قد ينصحك الطبيب بأن تتناول مكملات الكالسيوم وفيتامين د (الأقراص على سبيل المثال) لمدة لا تقل عن الأيام العشرة الأولى من تناول دواء <strong>زودريك</strong>&reg;. من الضروري أن تتبع هذه النصائح بعناية لكيلا يحدث نقص شديد في مستوى الكالسيوم لديك أثناء الفترة التالية لتلقي الدواء.</p><p dir="RTL">سيخبرك الطبيب فيما يتعلق بالأعراض المتعلقة بانخفاض مستوى الكالسيوم في الدم.</p><p dir="RTL"><strong>تناول دواء زودريك&reg; مع الأطعمة والمشروبات</strong></p><p dir="RTL">احرص على أن تشرب كمية كافية من السوائل (على الأقل كوب أو كوبين) قبل وبعد تناول هذا الدواء. وذلك وفقا لما نصحك به الطبيب. سيساعد ذلك في الوقاية من الإصابة بالجفاف. يمكنك تناول الطعام بصورة طبيعية في اليوم الذي ستتناول فيه هذا الدواء. تعد هذه الإرشادات في غاية الأهمية خاصة في المرضى الذين تناولون الأدوية المدرة للبول (أقراص الماء) والمرضى كبار السن (لمن في عمر 65 عاما أو أكثر).</p><p dir="RTL"><strong>إذا نسيت تناول جرعتك المحددة من الدواء</strong></p><p dir="RTL">استشر الطبيب أو المستشفى في أقرب وقت ممكن من أجل إعادة ترتيب موعد آخر لتلقي الدواء.</p><p dir="RTL"><strong>قبل التوقف عن تناول دواء زودريك&reg;</strong></p><p dir="RTL">إذا كنت ترغب في التوقف عن تناول دواء <strong>زودريك</strong>&reg; فيرجى مقابلة الطبيب في موعدك المحدد ومناقشة ذلك معه. سيقوم الطبيب حينها بنصحك بالحل الأمثل. كما سيقرر المدة اللازمة لتناول هذا الدواء.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي أو الممرضة إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية. فإن هذا الدواء يمكن أن بتسبب في ظهور بعض الأعراض الجانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL">الأعراض الجانبية المرتبطة بتناول الدواء عبر التنقيط الوريدي لأول مرة شائعة جدًا (حيث تحدث في أكثر من 30% من المرضى) ولكنها أقل شيوعًا في مرات التنقيط الوريدي اللاحقة. تحدث معظم الآثار الجانبية، مثل الحمى والقشعريرة، والألم في العضلات أو المفاصل، والصداع، في غضون الايام الثلاثة الأولى التالية لتناول جرعة دواء <strong>زودريك</strong>&reg;. عادة ما تكون الأعراض بسيطة إلى متوسطة وتختفي في غضون 3 أيام. قد بنصح الطبيب بتناول دواء مسكن للألم مثل إيبيبروفين أو باراسيتامول من أجل تقليل الأعراض الجانبية. تتناقص فرص الإصابة بهذه الأعراض الجانبية مع تناول الجرعات التالية من الدواء.</p><p dir="RTL"><strong>قد نكون بعض الأعراض الجانبية خطيرة</strong></p><p dir="RTL">الأعراض الجانبية المألوفة (تؤثر &rlm; ١ من بين ١٠ أشخاص)</p><p dir="RTL">شوهد وجود عدم انتظام في ضربات القلب (رجفان أذيني) في المرضى الذين يتناولون هذا الدواء لعلاج هشاشة العظم التي تحدث في سن اليأس (الفترة التالية لتوقف الحيض). ليس من الواضح حاليا إن كان هذا الدواء هو المتسبب في عدم انتظام في ضربات القلب، ولكن يجب عليك إبلاغ الطبيب إذا كنت تعاني من هذه الأعراض بعد تلقي هذا الدواء.</p><p dir="RTL"><strong>الأعراض الجانبية غير المألوفة (تؤثر ١ من بين ١٠٠ شخص):</strong></p><p dir="RTL">تورم واحمرار وألم وشعور بالحكة في العين أو حساسية العين تجاه الضوء.</p><p dir="RTL"><strong>الأعراض الجانبية النادرة جدا (تؤثر في أقل من ١ من بين 10،000 شخص)</strong></p><p dir="RTL">استشر الطبيب إذا كنت تعاني من ألم. في الأذن أو إفرازات من الأذن و/ أو عدوى في الأذن. يمكن أن تكون هذه الأعراض علامة لحدوث تلف في الأذن.</p><p dir="RTL"><strong>الأعراض الجانبية غير المعروفة (لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة):</strong></p><p dir="RTL">ألم في الفم و/أو الفك. تورم أو قرح غير ملتئمة داخل الفم أو إفرازات من الفك. أو الشعور بخدر أو ثقل في الفك أو تراخي الأسنان؛ حيث يمكن أن تكون هذه الأعراض علامة لحدوث تلف في عظم الفك (نخر عظمي). يجب إبلاغ الطبيب أو طبيب الأسنان على الفور إذا واجهتك أي من هذه الأعراض أثناء تناولك هذا الدواء أو بعد التوقف عن تناوله.</p><p dir="RTL">قد تحدث مشاكل &rlm; الكلية (مثل نقص الإخراج البولي). ينبغي أن يقوم الطبيب بإجراء فحوصات الدم من أجل فحص وظيفة الكلية قبل تناول كل جرعة من هذا الدواء. من الضروري شرب كوبين من السوائل على الأقل (مثل الماء) في غضون الساعات التي تسبق تناول هذا الدواء. وذلك وفقنا لما أوضحه لك مقدم الرعاية الصحية.</p><p dir="RTL">بجب استشارة الطبيب على الفور إذا عانيت من أي من هذه الأعراض المذكورة بالأعلى.</p><p dir="RTL"><strong>قد يتسبب دواء زودريك&reg; في بعض الأعراض الجانبية الأخرى</strong></p><p dir="RTL">الأعراض الجانبية المألوفة جدا (تؤثر في أكثر من ١ بين ١٠ أشخاص): ارتفاع درجة حرارة الجسم.</p><p dir="RTL"><strong>الأعراض الجانبية المألوفة (تؤثر في أكثر من ١ بين ١٠ أشخاص)</strong></p><p dir="RTL">الصداع، الدوخة، الشعور بالمرض، القيء، الإسهال، ألم في العضلات، ألم في العظام و / أو المفاصل، ألم في الظهر أو الذراعين أو الساقين، أعراض شبيهة بالأنفلونزا (مثل التعب، قشعريرة، ألم المفاصل والعضلات)، القشعريرة والشعور بالتعب وفقدان الرغبة والشعور بالضعف والألم مع الشعور بالإعياء والتورم و / أو الألم في موقع التنقيط الوريدي.</p><p dir="RTL">تم الإبلاغ عن الإصابة بأعراض ناتجة عن انخفاض نسبة الكالسيوم في الدم في المرضى الذين يعانون من مرض باجيت. مثل تقلص العضلات، أو خدر/ تنميل، والإحساس بالوخز خاصة في المنطقة المحيطة بالفم.</p><p dir="RTL"><strong>الأعراض الجانبية غير المألوفة (تؤثر ب ١ من بين ١٠٠ شخص):</strong></p><p dir="RTL">الانفلونزا التهابات الجهاز التنفسي العلوي، نقص عدد الخلايا الحمراء، فقدان الشهية، عدم النوم (الأرق)، النعاس الذي قد يشمل نقص في الانتباه والوعي، الإحساس بالوخز أو التنميل، التعب الشديد، الارتعاش، فقدان مؤقت للوعي، عدوى &rlm; العين أو تهيج العين أو التهاب يصاحبه ألم واحمرار في العين، الشعور بالدوار، ارتفاع ضغط الدم، احمرار الجسم، سعال، ضيق في التنفس، اضطراب في المعدة، ألم في البطن، إمساك، جفاف الفم، حرقة في المعدة، طفح جلدي، تعرق زائد، حكة، احمرار الجلد، ألم الرقبة، تصلب في العضلات، العظام و / أو المفاصل، تورم المفاصل، تشتجات في العضلات، ألم في الكتف، ألم في عضلات الصدر والقفص الصدري، التهاب المفاصل، ضعف عضلي، نتائج غير طبيعية في اختبار وظائف الكلى، تبول متكرر بصورة غير طبيعية، تورم في اليدين أو الكاحلين أو القدمين، العطش، ألم في الأسنان، اضطرابات في حاسة التذوق.</p><p dir="RTL"><strong>الأعراض الجانبية النادرة (تؤثر في ١ من بين ١،٠٠٠ شخص)</strong></p><p dir="RTL">حدوث كسر غير مألوف في عظم الفخّذ خاصة في المرضى الذين يتلقون علاجاً طويل الأجل لمرض هشاشة العظام وذلك في بعض الحالات النادرة.</p><p dir="RTL">يجب استشارة الطبيب إذا كنت تشعر بألم أو ضعف أو عدم ارتياح الفخذ أو الورك أو المنطقة الإربية لأن ذلك قد يعد مؤشر مبكر لحدوث كسر في عظم الفخذ. نقص مستويات الفوسفات في الدم</p><p dir="RTL"><strong>الأعراض الجانبية غير المعروفة (لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة):</strong></p><p dir="RTL">رد فعل تحسسي شديدة ويشمل ذلك الدوخة وصعوبة في التنفس، وتورم في الوجه والحلق بشكل رئيسي وانخفاض ضغط الدم والجفاف الناتج عن المعاناة من أعراض ما بعد تناول جرعة الدواء مثل ارتفاع درجة الحرارة والقيء والإسهال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لدى الطبيب أو الصيدلي أو الممرضة العلم الكافي بالطريقة المناسبة لتخزين هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على العبوة بعد كلمة EXP</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة لا تتجاوز 30 درجة منوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام الدواء بعد فتحه على الفور. لتجنب تلوثه بأي ميكروب خارجي. أما إذا لم يستخدم الدواء على الفور وهو مثل حالته الطبيعية وفي زمن التخزين المحدد له؛ والذي لا يتجاوز في الطبيعي أكثر من 24 ساعة عند درجت حرارة 2 -8 درجة مئوية، فإن ذلك يعد مسؤولية المستخدم. اترك المحلول اُلمبرد قليلا قبل الاستخدام كي يصل إلى درجة حرارة الغرفة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة في الدواء هي حمض الزوليدرونيك. تحتوي كل عبوة من الدواء على 100 مل من المحلول والذي يحتوي بدوره على 5 ملغم من حمض زوليدرونيك (في صورة أحادي الهيدرات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل 1 مل من المحلول على 0.05 ملغم من حمض زوليدرونيك (في صورة أحادي الهيدرات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات: مانيتول، وسترات الصوديوم والماء من أجل الحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زودريك&reg; هو محلول شفاف وبلا لون، يأتي الدواء في كيس / عبوة من البولي أوليفين بسعة 100 مل مع سدادة للعبوة، وجاهز للاستخدام المباشر في التنقيط الوريدي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:&nbsp; </strong><strong>&nbsp;</strong></p><p dir="RTL">إم إس فارما &ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو،2021
SPM-14-0021

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zodric® 5mg/100ml solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each bag with 100 ml of solution contains 5 mg zoledronic acid (as monohydrate).
Each ml of the solution contains 0.05 mg zoledronic acid (as monohydrate).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
Clear and colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of osteoporosis</p><p>&bull; In post-menopausal women</p><p>&bull; In adult men</p><p>At increased risk of fracture, including those with a recent low-trauma hip fracture.</p><p>Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy</p><p>&bull; In post-menopausal women</p><p>&bull; In adult men</p><p>At increased risk of fracture.</p><p>Treatment of Paget&#39;s disease of the bone in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Patients must be appropriately hydrated prior to administration of Zodric. This is especially important for the elderly (&ge;65 years) and for patients receiving diuretic therapy.</p><p>Adequate calcium and vitamin D intake are recommended in association with Zodric administration.</p><p><em><u>Osteoporosis</u></em></p><p>For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Zodric administered once a year.</p><p>The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Zodric on an individual patient basis, particularly after 5 or more years of use.</p><p>In patients with a recent low-trauma hip fracture, it is recommended to give the Zodric infusion at least two weeks after hip fracture repair (see section 5.1). In patients with a recent low-trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first Zodric infusion.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Paget&#39;s disease</u></em></p><p>For the treatment of Paget&#39;s disease, Zodric should be prescribed only by physicians with experience in the treatment of Paget&#39;s disease of the bone. The recommended dose is a single intravenous infusion of 5 mg Zodric. In patients with Paget&#39;s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zodric administration (see section 4.4).</p><p>Re-treatment of Paget&#39;s disease: After initial treatment with Zodric in Paget&#39;s disease, an extended remission period is observed in responding patients. Re-treatment consists of an additional intravenous infusion of 5 mg Zodric after an interval of one year or longer from initial treatment in patients who have relapsed. Limited data on re-treatment of Paget&#39;s disease are</p><p>available (see section 5.1).</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Patients with renal impairment</em></p><p>Zodric is contraindicated in patients with creatinine clearance &lt; 35 ml/min&nbsp;<u>(</u>see sections 4.3 and 4.4).</p><p>No dose adjustment is necessary in patients with creatinine clearance &ge; 35 ml/min.</p><p><em>Patients with hepatic impairment</em></p><p>No dose adjustment is required (see section 5.2).</p><p><em>Elderly (&ge; 65 years)</em></p><p>No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Zodric in children and adolescents below 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Intravenous use.</p><p>Zodric is administered via a vented infusion line and given slowly at a constant infusion rate. The infusion time must not be less than 15 minutes. For information on the infusion of Zodric, see section 6.6.</p><p>Patients treated with Zodric should be given the package leaflet and the patient reminder card.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance, to any bisphosphonates or to any of the excipients listed in section 6.1.
- Patients with hypocalcaemia (see section 4.4).
- Severe renal impairment with creatinine clearance < 35 ml/min (see section 4.4).
- Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal function</u></p><p>The use of Zodric in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.</p><p>Renal impairment has been observed following the administration of Zodric (see section 4.8), especially in patients with pre-existing renal dysfunction or other risks including advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy (see section 4.5), or dehydration occurring after Zodric administration. Renal impairment has been observed in patients after a single administration. Renal failure requiring dialysis or with a fatal outcome has rarely occurred in patients with underlying renal impairment or with any of the risk factors described above.</p><p>The following precautions should be taken into account to minimise the risk of renal adverse reactions:</p><p>&bull; Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each Zodric dose.</p><p>&bull; Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.</p><p>&bull; Monitoring of serum creatinine should be considered in at-risk patients.</p><p>&bull; Zodric should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).</p><p>&bull; Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Zodric.</p><p>&bull; A single dose of Zodric should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).</p><p><u>Hypocalcaemia</u></p><p>Pre-existing hypocalcaemia must be treated by adequate intake of calcium and vitamin D before initiating therapy with Zodric (see section 4.3). Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve, intestinal calcium malabsorption). Physicians should consider clinical monitoring for these patients.</p><p>Elevated bone turnover is a characteristic of Paget&#39;s disease of the bone. Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of Zodric (see section 4.8).</p><p>Adequate calcium and vitamin D intake are recommended in association with Zodric administration. In addition, in patients with Paget&#39;s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zodric administration (see section 4.2).</p><p>Patients should be informed about symptoms of hypocalcaemia and receive adequate clinical monitoring during the period of risk. Measurement of serum calcium before infusion of Zodric is recommended for patients with Paget&acute;s disease.</p><p>Severe and occasionally incapacitating bone, joint and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including zoledronic acid (see section 4.8).</p><p><u>Osteonecrosis of the jaw (ONJ)</u></p><p>ONJ has been reported in the post-marketing setting in patients receiving Zodric (zoledronic acid) for osteoporosis (see section 4.8).</p><p>The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Zodric in patients with concomitant risk factors.</p><p>The following should be considered when evaluating a patient&#39;s risk of developing ONJ:</p><p>- Potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.</p><p>- Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p><p>- Concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck.</p><p>- Poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, invasive dental procedures, e.g. tooth extractions.</p><p>All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, non-healing of sores or discharge during treatment with zoledronic acid. While on treatment, invasive dental procedures should be performed with caution and avoided in close proximity to zoledronic acid treatment.</p><p>The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p><u>Osteonecrosis of the external auditory canal</u></p><p>Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.</p><p><u>Atypical fractures of the femur</u></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p><u>General</u></p><p>The incidence of post-dose symptoms occurring within the first three days after administration of Zodric can be reduced with the administration of paracetamol or ibuprofen shortly following Zodric administration.</p><p>Other products containing zoledronic acid as an active substance are available for oncology indications. Patients being treated with Zodric should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml vial of Zodric, i.e. essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies with other medicinal products have been performed. Zoledronic acid is not systemically metabolised and does not affect human cytochrome P450 enzymes&nbsp;<em>in vitro&nbsp;</em>(see section 5.2). Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound medicinal products are therefore unlikely.</p><p>Zoledronic acid is eliminated by renal excretion. Caution is indicated when zoledronic acid is administered in conjunction with medicinal products that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration) (see section 4.4).</p><p>In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidney may increase</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Zodric is not recommended in women of childbearing potential.</p><p><u>Pregnancy</u></p><p>Zodric is contraindicated during pregnancy (see section 4.3). There are no adequate data on the use of zoledronic acid in pregnant women. Studies in animals with zoledronic acid have shown reproductive toxicological effects including malformations (see section 5.3). The potential risk for humans is unknown.</p><p><u>Breast-feeding</u></p><p>Zodric is contraindicated during breast-feeding (see section 4.3). It is unknown whether zoledronic acid is excreted into human milk.</p><p><u>Fertility</u></p><p>Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered related to the compound&#39;s inhibition of skeletal calcium mobilisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results precluded determining a definitive effect of Zodric on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness, may affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the first, second and third infusion, respectively. Incidence of individual adverse reactions following the first infusion was: pyrexia (17.1%), myalgia (7.8%), influenza-like illness (6.7%), arthralgia (4.8%) and headache (5.1%). The incidence of these reactions decreased markedly with subsequent annual doses of Zodric. The majority of these reactions occur within the first three days following Zodric administration. The majority of these reactions were mild to moderate and resolved within three days of the event onset. The percentage of patients who experienced adverse reactions was lower in a smaller study (19.5%, 10.4%, 10.7% after the first, second and third infusion, respectively), where prophylaxis against adverse reactions was used.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Influenza, nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including rare cases of bronchospasm, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Hypocalcaemia*</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Lethargy, paraesthesia, somnolence, tremor, syncope, dysgeusia</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Ocular hyperaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Conjunctivitis, eye pain</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Uveitis, episcleritis, iritis</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Scleritis and parophthalmia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hypertension, flushing</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Hypotension (some of the patients had underlying risk factors)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Cough, dyspnoea</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Dyspepsia, abdominal pain upper, abdominal pain, gastro-oesophageal reflux disease, constipation, dry mouth, oesophagitis, toothache, gastritis<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Rash, hyperhidrosis, pruritus, erythema</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Myalgia, arthralgia, bone pain, back pain, pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Neck pain, musculoskeletal stiffness, joint swelling, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, joint stiffness, arthritis, muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Atypical subtrochanteric and diaphyseal femoral fractures&dagger; (bisphosphonate class adverse reaction)</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em></p></td><td style="vertical-align:top"><p>Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Osteonecrosis of the jaw (see sections 4.4 and 4.8 Class effects)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Blood creatinine increased, pollakiuria, proteinuria</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Renal impairment. Rare cases of renal failure requiring dialysis and rare cases with a fatal outcome have been reported in patients with pre-existing renal dysfunction or other risk factors such as advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, or dehydration in the post infusion period (see sections 4.4 and 4.8 Class effects)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Influenza-like illness, chills, fatigue, asthenia, pain, malaise, infusion site reaction</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Peripheral oedema, thirst, acute phase reaction, non-cardiac chest pain</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Dehydration secondary to post-dose symptoms such as pyrexia, vomiting and diarrhoea</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>C-reactive protein increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Blood calcium decreased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>#</sup>&nbsp;Observed in patients taking concomitant glucocorticosteroids.</p><p>* Common in Paget&#39;s disease only.</p><p>** Based on post-marketing reports. Frequency cannot be estimated from available data.</p><p>&dagger; Identified in post-marketing experience.</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em><u>Atrial fibrillation</u></em></p><p>In the HORIZON &ndash; Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving Zodric and placebo, respectively. The rate of atrial fibrillation serious adverse events was increased in patients receiving Zodric (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852). The mechanism behind the increased incidence of atrial fibrillation is unknown. In the osteoporosis trials (PFT, HORIZON - Recurrent Fracture Trial [RFT]) the pooled atrial fibrillation incidences were comparable between Zodric (2.6%) and placebo (2.1%). For atrial fibrillation serious adverse events the pooled incidences were 1.3% for Zodric and 0.8% for placebo.</p><p><em><u>Class effects</u></em></p><p><em>Renal impairment</em></p><p>Zoledronic acid has been associated with renal impairment manifested as deterioration in renal function (i.e. increased serum creatinine) and in rare cases acute renal failure. Renal impairment has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal dysfunction or additional risk factors (e.g advanced age, oncology patients with chemotherapy, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, severe dehydration), with the majority of them receiving a 4 mg dose every 3&ndash;4 weeks, but it has been observed in patients after a single administration.</p><p>In clinical trials in osteoporosis, the change in creatinine clearance (measured annually prior to dosing) and the incidence of renal failure and impairment was comparable for both the Zodric and placebo treatment groups over three years. There was a transient increase in serum creatinine observed within 10 days in 1.8% of Zodric-treated patients versus 0.8% of placebo-treated patients.</p><p><em>Hypocalcaemia</em></p><p>In clinical trials in osteoporosis, approximately 0.2% of patients had notable declines of serum calcium levels (less than 1.87 mmol/l) following Zodric administration. No symptomatic cases of hypocalcaemia were observed.</p><p>In the Paget&#39;s disease trials, symptomatic hypocalcaemia was observed in approximately 1% of patients, in all of whom it resolved.</p><p>Based on laboratory assessment, transient asymptomatic calcium levels below the normal reference range (less than 2.10 mmol/l) occurred in 2.3% of Zodric-treated patients in a large clinical trial compared to 21% of Zodric-treated patients in the Paget&#39;s disease trials. The frequency of hypocalcaemia was much lower following subsequent infusions.</p><p>All patients received adequate supplementation with vitamin D and calcium in the post-menopausal osteoporosis trial, the prevention of clinical fractures after hip fracture trial, and the Paget&#39;s disease trials (see also section 4.2). In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to Zodric administration (see section 4.2).</p><p><em>Local reactions</em></p><p>In a large clinical trial, local reactions at the infusion site, such as redness, swelling and/or pain, were reported (0.7%) following the administration of zoledronic acid.</p><p><em>Osteonecrosis of the jaw</em></p><p>Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, including zoledronic acid (see section 4.4). In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with Zodric and one patient treated with placebo. Cases of ONJ have been reported in the post-marketing setting for Zodric.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.65pt;margin-top:6.25pt;width:375.05pt;height:109pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right dir=RTL style='text-align:left;mso-layout-grid-align:
    none;text-autospace:none'><span dir=LTR style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>- The National Pharmacovigilance
    and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Call NPC
    at +966-11-2038222<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Toll free
    phone: 8002490000<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Website:
    www.sfda.gov.sa/npc<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-indent:-.25in'><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="150" alt="Text Box: - The National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222
•	Toll free phone: 8002490000
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa
•	Website: www.sfda.gov.sa/npc

" src="file:///C:/Users/ABDULL~1.ALO/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose is limited. Patients who have received doses higher than those recommended should be carefully monitored. In the event of overdose leading to clinically significant hypocalcaemia, reversal may be achieved with supplemental oral calcium and/or an intravenous infusion of calcium gluconate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates, ATC code: M05BA08</p><p><u>Mechanism of action</u></p><p>Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption.</p><p><u>Pharmacodynamic effects</u></p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone.</p><p>The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The long duration of action of zoledronic acid is attributable to its high binding affinity for the active site of farnesyl pyrophosphate (FPP) synthase and its strong binding affinity to bone mineral.</p><p>Zodric treatment rapidly reduced the rate of bone turnover from elevated post-menopausal levels with the nadir for resorption markers observed at 7 days, and for formation markers at 12 weeks. Thereafter bone markers stabilised within the pre-menopausal range. There was no progressive reduction of bone turnover markers with repeated annual dosing.</p><p><u>Clinical efficacy in the treatment of post-menopausal osteoporosis (PFT)</u></p><p>The efficacy and safety of Zodric 5 mg once a year for 3 consecutive years were demonstrated in post-menopausal women (7,736 women aged 65&ndash;89 years) with either: a femoral neck bone mineral density (BMD) with a T-score &le; &ndash;1.5 and at least two mild or one moderate existing vertebral fracture(s); or a femoral neck BMD T-score &le; &ndash;2.5 with or without evidence of existing vertebral fracture(s). 85% of patients were bisphosphonate-na&iuml;ve. Women who were evaluated for the incidence of vertebral fractures did not receive concomitant osteoporosis therapy, which was allowed for women contributing to the hip and all clinical fracture evaluations. Concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates. All women received 1,000 to 1,500 mg elemental calcium and 400 to 1,200 IU of vitamin D supplements daily.</p><p><em><u>Effect on morphometric vertebral fractures</u></em></p><p>Zodric significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one year timepoint (see Table 2).</p><p><strong>Table 2 Summary of vertebral fracture efficacy at 12, 24 and 36 months</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Outcome</p></td><td style="vertical-align:top"><p>Zodric (%)</p></td><td style="vertical-align:top"><p>Placebo (%)</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture incidence % (CI)</p></td><td style="vertical-align:top"><p>Relative reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;1 year)</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>2.2 (1.4, 3.1)</p></td><td style="vertical-align:top"><p>60 (43, 72)**</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;2 year)</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>5.5 (4.4, 6.6)</p></td><td style="vertical-align:top"><p>71 (62, 78)**</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;3 year)</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>7.6 (6.3, 9.0)</p></td><td style="vertical-align:top"><p>70 (62, 76)**</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>** p &lt;0.0001</p></td></tr></tbody></table><p>Zodric-treated patients aged 75 years and older exhibited a 60% reduction in the risk of vertebral fractures compared to placebo patients (p&lt;0.0001).</p><p><em><u>Effect on hip fractures</u></em></p><p>Zodric demonstrated a consistent effect over 3 years, resulting in a 41% reduction in the risk of hip fractures (95% CI, 17% to 58%). The hip fracture event rate was 1.44% for Zodric-treated patients compared to 2.49% for placebo-treated patients. The risk reduction was 51% in bisphosphonate-na&iuml;ve patients and 42% in patients allowed to take concomitant osteoporosis therapy.</p><p><em><u>Effect on all clinical fractures</u></em></p><p>All clinical fractures were verified based on the radiographic and/or clinical evidence. A summary of results is presented in Table 3.</p><p><strong>Table 3 Between treatment comparisons of the incidence of key clinical fracture variables over 3 years</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Outcome</p></td><td style="vertical-align:top"><p>Zodric (N=3,875) event rate (%)</p></td><td style="vertical-align:top"><p>Placebo (N=3,861) event rate (%)</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture event rate % (CI)</p></td><td style="vertical-align:top"><p>Relative risk reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>Any clinical fracture (1)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>4.4 (3.0, 5.8)</p></td><td style="vertical-align:top"><p>33 (23, 42)**</p></td></tr><tr><td style="vertical-align:top"><p>Clinical vertebral fracture (2)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2.1 (1.5, 2.7)</p></td><td style="vertical-align:top"><p>77 (63, 86)**</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fracture (1)</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>2.7 (1.4, 4.0)</p></td><td style="vertical-align:top"><p>25 (13, 36)*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p-value &lt;0.001, **p-value &lt;0.0001</p><p>(1) Excluding finger, toe and facial fractures</p><p>(2) Including clinical thoracic and clinical lumbar vertebral fractures</p></td></tr></tbody></table><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>Zodric significantly increased BMD at the lumbar spine, hip, and distal radius relative to treatment with placebo at all timepoints (6, 12, 24 and 36 months). Treatment with Zodric resulted in a 6.7% increase in BMD at the lumbar spine, 6.0% at the total hip, 5.1% at the femoral neck, and 3.2% at the distal radius over 3 years as compared to placebo.</p><p><em><u>Bone histology</u></em></p><p>Bone biopsies were obtained from the iliac crest 1 year after the third annual dose in 152 post-menopausal patients with osteoporosis treated with Zodric (N=82) or placebo (N=70). Histomorphometric analysis showed a 63% reduction in bone turnover. In patients treated with Zodric, no osteomalacia, marrow fibrosis or woven bone formation was detected. Tetracycline label was detectable in all but one of 82 biopsies obtained from patients on Zodric. Microcomputed tomography (&mu;CT) analysis demonstrated increased trabecular bone volume and preservation of trabecular bone architecture in patients treated with Zodric compared to placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Bone turnover markers</u></em></p><p>Bone specific alkaline phosphatase (BSAP), serum N-terminal propeptide of type I collagen (P1NP) and serum beta-C-telopeptides (b-CTx) were evaluated in subsets ranging from 517 to 1,246 patients at periodic intervals throughout the study. Treatment with a 5 mg annual dose of Zodric significantly reduced BSAP by 30% relative to baseline at 12 months which was sustained at 28% below baseline levels at 36 months. P1NP was significantly reduced by 61% below baseline levels at 12 months and was sustained at 52% below baseline levels at 36 months. B-CTx was significantly reduced by 61% below baseline levels at 12 months and was sustained at 55% below baseline levels at 36 months. During this entire time period bone turnover markers were within the pre-menopausal range at the end of each year. Repeat dosing did not lead to further reduction of bone turnover markers.</p><p><em><u>Effect on height</u></em></p><p>In the three-year osteoporosis study standing height was measured annually using a stadiometer. The Zodric group revealed approximately 2.5 mm less height loss compared to placebo (95% CI: 1.6 mm, 3.5 mm) [p&lt;0.0001].</p><p><em><u>Days of disability</u></em></p><p>Zodric significantly reduced the mean days of limited activity and the days of bed rest due to back pain by 17.9 days and 11.3 days respectively compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p&lt;0.01).</p><p><u>Clinical efficacy in the treatment of osteoporosis in patients at increased risk of fracture after a recent hip fracture (RFT)</u></p><p>The incidence of clinical fractures, including vertebral, non-vertebral and hip fractures, was evaluated in 2,127 men and women aged 50-95 years (mean age 74.5 years) with a recent (within 90 days) low-trauma hip fracture who were followed for an average of 2 years on study treatment (Zodric). Approximately 42% of patients had a femoral neck BMD T-score below -2.5 and approximately 45% of the patients had a femoral neck BMD T-score above -2.5. Zodric was administered once a year, until at least 211 patients in the study population had confirmed clinical fractures. Vitamin D levels were not routinely measured but a loading dose of vitamin D (50,000 to 125,000 IU orally or by intramuscular route) was given to the majority of patients 2 weeks prior to infusion. All participants received 1,000 to 1,500 mg of elemental calcium plus 800 to 1,200 IU of vitamin D supplementation per day. Ninety-five percent of the patients received their infusion two or more weeks after the hip fracture repair and the median timing of infusion was approximately six weeks after the hip fracture repair. The primary efficacy variable was the incidence of clinical fractures over the duration of the study.</p><p><em><u>Effect on all clinical fractures</u></em></p><p>The incidence rates of key clinical fracture variables are presented in Table 4.</p><p><strong>Table 4 Between treatment comparisons of the incidence of key clinical fracture variables</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Outcome</p></td><td style="vertical-align:top"><p>Zodric (N=1,065) event rate (%)</p></td><td style="vertical-align:top"><p>Placebo (N=1,062) event rate (%)</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture event rate % (CI)</p></td><td style="vertical-align:top"><p>Relative risk reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>Any clinical fracture (1)</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>13.9</p></td><td style="vertical-align:top"><p>5.3 (2.3, 8.3)</p></td><td style="vertical-align:top"><p>35 (16, 50)**</p></td></tr><tr><td style="vertical-align:top"><p>Clinical vertebral fracture (2)</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>2.1 (0.5, 3.7)</p></td><td style="vertical-align:top"><p>46 (8, 68)*</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fracture (1)</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>3.1 (0.3, 5.9)</p></td><td style="vertical-align:top"><p>27 (2, 45)*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p-value &lt;0.05, **p-value &lt;0.01</p><p>(1) Excluding finger, toe and facial fractures</p><p>(2) Including clinical thoracic and clinical lumbar vertebral fractures</p></td></tr></tbody></table><p>The study was not designed to measure significant differences in hip fracture, but a trend was seen towards reduction in new hip fractures.</p><p>All cause mortality was 10% (101 patients) in the Zodric-treated group compared to 13% (141 patients) in the placebo group. This corresponds to a 28% reduction in the risk of all cause mortality (p=0.01).</p><p>The incidence of delayed hip fracture healing was comparable between Zodric (34 [3.2%]) and placebo (29 [2.7%]).</p><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>In the HORIZON-RFT study Zodric treatment significantly increased BMD at the total hip and femoral neck relative to treatment with placebo at all timepoints. Treatment with Zodric resulted in an increase in BMD of 5.4% at the total hip and 4.3% at the femoral neck over 24 months as compared to placebo.</p><p><u>Clinical efficacy in men</u></p><p>In the HORIZON-RFT study 508 men were randomised into the study and 185 patients had BMD assessed at 24 months. At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with Zodric as compared to the effects observed in post-menopausal women in the HORIZON-PFT study. The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with Zodric versus 8.7% for placebo.</p><p>In another study in men (study CZOL446M2308) an annual infusion of Zodric was non-inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline.</p><p><u>Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy</u></p><p>The efficacy and safety of Zodric in the treatment and prevention of osteoporosis associated with long-term systemic glucocorticoid therapy were assessed in a randomised, multicentre, double-blind, stratified, active-controlled study of 833 men and women aged 18-85 years (mean age for men 56.4 years; for women 53.5 years) treated with &gt; 7.5 mg/day oral prednisone (or equivalent). Patients were stratified with respect to duration of glucocorticoid use prior to randomisation (&le; 3 months versus &gt; 3 months). The duration of the trial was one year. Patients were randomised to either Zodric 5 mg single infusion or to oral risedronate 5 mg daily for one year. All participants received 1,000 mg elemental calcium plus 400 to 1,000 IU vitamin D supplementation per day. Efficacy was demonstrated if non-inferiority to risedronate was shown sequentially with respect to the percentage change in lumbar spine BMD at 12 months relative to baseline in the treatment and prevention subpopulations, respectively. The majority of patients continued to receive glucocorticoids for the one year duration of the trial.</p><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>The increases in BMD were significantly greater in the Zodric-treated group at the lumbar spine and femoral neck at 12 months compared to risedronate (all p&lt;0.03). In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, Zodric increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p&lt;0.001). In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, Zodric increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p&lt;0.001). The study was not powered to show a reduction in clinical fractures compared to risedronate. The incidence of fractures was 8 for Zodric-treated patients versus 7 for risedronate-treated patients (p=0.8055).</p><p><u>Clinical efficacy in the treatment of Paget&#39;s disease of the bone</u></p><p>Zodric was studied in male and female patients aged above 30 years with primarily mild to moderate Paget&#39;s disease of the bone (median serum alkaline phosphatase level 2.6&ndash;3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.</p><p>The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials. After 6 months, Zodric showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p&lt;0.001).</p><p>In the pooled results, a similar decrease in pain severity and pain interference scores relative to baseline were observed over 6 months for Zodric and risedronate.</p><p>Patients who were classified as responders at the end of the 6 month core study were eligible to enter an extended follow-up period. Of the 153 Zodric-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a mean duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%). The mean time of ending the Extended Observation Period due to the need for Paget&#39;s re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).</p><p>Six patients who achieved therapeutic response 6 months after treatment with Zodric and later experienced disease relapse during the extended follow-up period were re-treated with Zodric after a mean time of 6.5 years from initial treatment to re-treatment. Five of the 6 patients had SAP within the normal range at month 6 (Last Observation Carried Forward, LOCF).</p><p>Bone histology was evaluated in 7 patients with Paget&#39;s disease 6 months after treatment with 5 mg zoledronic acid. Bone biopsy results showed bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defects. These results were consistent with biochemical marker evidence of normalisation of bone turnover.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Zodric in all subsets of the paediatric population in Paget&#39;s disease of the bone, osteoporosis in post-menopausal women at an increased risk of fracture, osteoporosis in men at increased risk of fracture and prevention of clinical fractures after a hip fracture in men and women (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and multiple 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients yielded the following pharmacokinetic data, which were found to be dose independent.</p><p><u>Distribution</u></p><p>After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.</p><p><u>Elimination</u></p><p>Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t<sub>&frac12;&alpha;&nbsp;</sub>0.24 and t<sub>&frac12;&beta;</sub>&nbsp;1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t<sub>&frac12;&gamma;</sub>&nbsp;146 hours. There was no accumulation of the active substance in plasma after multiple doses given every 28 days. The early disposition phases (&alpha; and &beta;, with t<sub>&frac12;</sub>&nbsp;values above) presumably represent rapid uptake into bone and excretion via the kidneys.</p><p>Zoledronic acid is not metabolized and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. This uptake into bone is common for all bisphosphonates and is presumably a consequence of the structural analogy to pyrophosphate. As with other bisphosphonates, the retention time of zoledronic acid in bones is very long. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race or body weight. The inter- and intra-subject variation for plasma clearance of zoledronic acid was shown to be 36% and 34%, respectively. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p><u>Pharmacokinetic/pharmacodynamic relationships</u></p><p>No interaction studies with other medicinal products have been performed with zoledronic acid. Since zoledronic acid is not metabolized in humans and the substance was found to have little or no capacity as a direct-acting and/or irreversible metabolism-dependent inhibitor of P450 enzymes, zoledronic acid is unlikely to reduce the metabolic clearance of substances which are metabolized via the cytochrome P450 enzyme systems. Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and binding is concentration independent. Therefore, interactions resulting from displacement of highly protein-bound medicinal products are unlikely.</p><p><u>Special populations (see section 4.2)</u></p><p><em><u>Renal impairment</u></em></p><p>The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range 22 to 143 ml/min) in the 64 patients studied. Small observed increases in AUC<sub>(0-24hr)</sub>, by about 30% to 40% in mild to moderate renal impairment, compared to a patient with normal renal function, and lack of accumulation of drug with multiple doses irrespective of renal function, suggest that dose adjustments of zoledronic acid in mild (Cl<sub>cr&nbsp;</sub>= 50&ndash;80 ml/min) and moderate renal impairment down to a creatinine clearance of 35 ml/min are not necessary. The use of Zodric in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute toxicity</u></p><p>The highest non-lethal single intravenous dose was 10 mg/kg body weight in mice and 0.6 mg/kg in rats. In the single-dose dog infusion studies, 1.0 mg/kg (6 fold the recommended human therapeutic exposure based on AUC) administered over 15 minutes was well tolerated with no renal effects.</p><p><u>Subchronic and chronic toxicity</u></p><p>In the intravenous infusion studies, renal tolerability of zoledronic acid was established in rats when given 0.6 mg/kg as 15-minute infusions at 3-day intervals, six times in total (for a cumulative dose that corresponded to AUC levels about 6 times the human therapeutic exposure) while five 15-minute infusions of 0.25 mg/kg administered at 2&ndash;3-week intervals (a cumulative dose that corresponded to 7 times the human therapeutic exposure) were well tolerated in dogs. In the intravenous bolus studies, the doses that were well-tolerated decreased with increasing study duration: 0.2 and 0.02 mg/kg daily was well tolerated for 4 weeks in rats and dogs, respectively but only 0.01 mg/kg and 0.005 mg/kg in rats and dogs, respectively, when given for 52 weeks.</p><p>Longer-term repeat administration at cumulative exposures sufficiently exceeding the maximum intended human exposure produced toxicological effects in other organs, including the gastrointestinal tract and liver, and at the site of intravenous administration. The clinical relevance of these findings is unknown. The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&#39;s pharmacological antiresorptive activity.</p><p><u>Reproduction toxicity</u></p><p>Teratology studies were performed in two species, both via subcutaneous administration. Teratogenicity was observed in rats at doses &ge; 0.2 mg/kg and was manifested by external, visceral and skeletal malformations. Dystocia was observed at the lowest dose (0.01 mg/kg body weight) tested in rats. No teratological or embryo/fetal effects were observed in rabbits, although maternal toxicity was marked at 0.1 mg/kg due to decreased serum calcium levels.</p><p><u>Mutagenicity and carcinogenic potential</u></p><p>Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Sodium citrate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zodric must not be allowed to come into contact with any calcium-containing solutions. Zodric must not be mixed or given intravenously with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After opening: 24 hours at 2°C - 8°C
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyolefin Bags 100ml with Plug for bag</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only.</p><p>Only clear solution free from particles and discoloration should be used.</p><p>If refrigerated, allow the refrigerated solution to reach room temperature before administration. Aseptic techniques must be followed during the preparation of the infusion.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Grand center 1st floor,
Alrabiea area - King Abdulaziz Road,
Riyadh, Kingdome Saudi Arabia
P.O.Box 54850
Phone: +966112790122
RegulatoryKSA@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apr-19
SPC-011-0419-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>